Document Detail


Efficacy and safety of 3-day azithromycin versus 5-day moxifloxacin for the treatment of acute bacterial exacerbations of chronic bronchitis.
MedLine Citation:
PMID:  17189096     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Antibiotic therapy is of clinical benefit in certain patients with acute exacerbations of chronic bronchitis (AECB). In this randomised, investigator-blinded, multicentre trial, azithromycin (500mg once a day (qd) for 3 days) was compared with moxifloxacin (400mg qd for 5 days) for the treatment of outpatients with AECB (forced expiratory volume in 1s (FEV(1)) >35%). Of 342 patients randomised to either treatment, 169 received azithromycin and 173 received moxifloxacin. The mean age in the azithromycin and moxifloxacin groups was 56.4 years and 55.5 years, respectively. In the intent-to-treat analysis, clinical success rates for azithromycin and moxifloxacin were comparable at Days 10-12 (90% versus 90%, respectively) and Days 22-26 (81% versus 82%, respectively). Among patients who were culture-positive at baseline for Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis or Haemophilus parainfluenzae, clinical efficacy for azithromycin versus moxifloxacin at Days 10-12 was 93% versus 84%, respectively, and at Days 22-26 it was 89% versus 73%, respectively. The incidence of at least one treatment-related adverse event (AE) in the azithromycin and moxifloxacin groups was 18.3% and 19.1%, respectively. The most common AEs were diarrhoea, nausea, abdominal pain and vaginitis. Most treatment-related AEs were of mild or moderate severity, with no serious treatment-related AEs. One subject in the moxifloxacin group discontinued treatment owing to a treatment-related AE (precordial pain and dry throat). Compliance with both regimens was >90%. Three-day azithromycin and 5-day moxifloxacin demonstrate comparable efficacy and safety for the treatment of AECB in outpatients.
Authors:
Marcus Zervos; Fernando J Martinez; Guy W Amsden; Constance D Rothermel; Glenda Treadway
Related Documents :
6165096 - Occurrence of hla types in h. influenzae type b disease.
17601896 - Comparing ceftriaxone plus azithromycin or doxycycline for pelvic inflammatory disease:...
21952656 - Electroacupuncture versus morphine for the postoperative control pain in dogs.
17984346 - No depletion of wolbachia from onchocerca volvulus after a short course of rifampin and...
15329766 - Behcet's disease: experience in a tertiary rheumatology centre in singapore and a revie...
683276 - Preoperative carcinoembryonic antigen level as a prognostic indicator in colorectal can...
Publication Detail:
Type:  Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  International journal of antimicrobial agents     Volume:  29     ISSN:  0924-8579     ISO Abbreviation:  Int. J. Antimicrob. Agents     Publication Date:  2007 Jan 
Date Detail:
Created Date:  2006-12-25     Completed Date:  2007-03-20     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9111860     Medline TA:  Int J Antimicrob Agents     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  56-61     Citation Subset:  IM    
Affiliation:
Henry Ford Hospital, Detroit, MI 48202, USA. mzervos1@hfhs.org
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Abdominal Pain / chemically induced
Adult
Aged
Anti-Bacterial Agents / adverse effects,  pharmacology,  therapeutic use
Aza Compounds / adverse effects,  pharmacology,  therapeutic use*
Azithromycin / adverse effects,  pharmacology,  therapeutic use*
Bronchitis, Chronic / drug therapy*,  microbiology
Drug Administration Schedule
Female
Haemophilus influenzae / drug effects,  isolation & purification
Haemophilus parainfluenzae / drug effects,  isolation & purification
Humans
Male
Microbial Sensitivity Tests
Middle Aged
Moraxella (Branhamella) catarrhalis / drug effects,  isolation & purification
Nausea / chemically induced
Patient Compliance
Quinolines / adverse effects,  pharmacology,  therapeutic use*
Single-Blind Method
Streptococcus pneumoniae / drug effects,  isolation & purification
Treatment Outcome
Vaginitis / chemically induced
Chemical
Reg. No./Substance:
0/Anti-Bacterial Agents; 0/Aza Compounds; 0/Quinolines; 0/moxifloxacin; 83905-01-5/Azithromycin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Colistin offers prolonged survival in experimental infection by multidrug-resistant Acinetobacter ba...
Next Document:  Fosfomycin in the treatment of extended spectrum beta-lactamase-producing Escherichia coli-related l...